Oral lichenoid lesions as an immune‐related adverse event: A rare case report and literature review-Reference-Cited by-同舟云学术

Oral lichenoid lesions as an immune‐related adverse event: A rare case report and literature review

Published:2024-09-07 Issue: Volume: Page:
ISSN:1348-8643
Container-title:Oral Science International
language:en
Short-container-title:Oral Science International

Author:

Okamura Takeshi¹²^ORCID,Koshinuma Shinya¹,Noujima Mai³,Sugiura Shuji⁴,Fujimoto Noriki⁴,Takaoka Kazuki¹

Affiliation:

1. Department of Oral and Maxillofacial Surgery Shiga University of Medical Science Otsu Shiga Japan

2. Department of Oral and Maxillofacial Surgery, School of Life Dentistry at Tokyo The Nippon Dental University Tokyo Japan

3. Department of Human Pathology Shiga University of Medical Science Otsu Shiga Japan

4. Department of Dermatology Shiga University of Medical Science Otsu Shiga Japan

Abstract

AbstractBackgroundReports of oral lichenoid lesions (OLLs) as an immune‐related adverse event (irAE) are rare.Case presentationAn 81‐year‐old man was visited with a complaint of severe pain in the oral mucosa. He had received nivolumab for relapsed malignant melanoma. Pathological examination showed acanthotic and destructive changes in the epithelium with inflammatory infiltrates and CD8 positivity. Based on these findings, the diagnosis was OLL as an irAE. Oral prednisolone was started, and the lesion gradually resolved.ConclusionThe literature review suggested that OLL can appear as an irAE on the buccal mucosa and tongue after a varying number of cycles of immune checkpoint inhibitors. Routine surveillance of the oral mucosa is needed.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/osi2.1270

Reference17 articles.

1. Severe Oral Ulcers Associated With Nivolumab Treatment

2. Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings

3. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review

4. Drug-induced oral lichenoid reaction during nivolumab therapy

5. A case of oral lichenoid reaction during nivolumab therapy